Panobinostat is a Small Molecule owned by Secura Bio, and is involved in 10 clinical trials, of which 3 were completed, and 7 are ongoing.

Panobinostat is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs at nanomolar concentrations. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. This results in increased acetylation of histone proteins, an epigenetic alteration that results in a relaxing of chromatin, leading to transcriptional activation.

The revenue for Panobinostat is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Panobinostat NPV Report.

Panobinostat was originated by Novartis and is currently owned by Secura Bio. Novartis is the other company associated in development or marketing of Panobinostat.

Panobinostat Overview

Panobinostat (Farydak) is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. It is formulated as hard gelatin capsules for the oral route of administration. Panobinostat is indicated in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.

Panobinostat (LBH589) is under development for the treatment of pediatric patients with diffuse intrinsic pontine glioma (DIPG), graft versus host disease (GVHD), sickle cell disease, HIV-1 infections. The drug candidate was also under development for the treatment of Huntington's disease, hematological tumors such as thyroid cancer, multiple myeloma, acute myelocytic leukemia, myelodysplastic syndrome, diffuse large B-cell lymphoma, thrombocythaemia myelofibrosis, myelofibrosis, refractory cutaneous T-cell lymphoma, post-polycythemia vera myelofibrosis (PPV-MF), acute lymphocytic leukemia, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, recurrent high grade glioma, chronic lymphocytic leukemia (CLL), esophageal cancer, gastric cancer, colorectal cancer, head and neck cancer, Hodgkin lymphoma, small-cell lung cancer, adult T-cell lymphoma, mantle cell lymphoma, thyroid cancer, adult T-cell leukemia, chronic myelocytic leukemia, osteosarcoma, malignant rhabdoid tumor, atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma, non-small cell lung cancer, hepatocellular carcinoma, metastatic melanoma, HER -2 positive metastatic breast cancer, neuroendocrine tumors, metastatic renal cell carcinoma, refractory chronic myelocytic leukemia and recurrent malignant gliomas.

Novartis Overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.

Quick View – Panobinostat

Report Segments
  • Innovator (NME)
Drug Name
  • Panobinostat
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Hematological Disorders
  • Immunology
  • Infectious Disease
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.